
Operations Office

Telephone (507) 284-2172



Date: May 26, 2006

To: NCCTG Primary Clinical Research Associates

From: Patricia A. Mann
Protocol Development Coordinator

Re: N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR[®] Depot) for Symptomatic Ascites in Cancer Patients

A note has been added to the End of Active Treatment Form. If a patient receives two full years of treatment no Event Monitoring is required. Please discard all previous versions of this form.

Please call or e-mail me at mann.patricia@mayo.edu if you have questions.

Thank you.